April 10, 2006

In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate

Key Points

Key points are not available for this paper at this time.

Abstract

We provide first proof of the in vivo activation of a causative gene by valproic acid in an inherited disease and discuss strategies of monitoring drug response in patients.

AI에게 질문

Bookmark

AI에게 질문

Bookmark

Cite This Study

Brichta et al. (Mon,) studied this question.

synapsesocial.com/papers/69dd61dc7808b00a4799d6c3 https://doi.org/https://doi.org/10.1002/ana.20836

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy.1978 · 469 citations
2Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays2000 · 3,891 citations
3Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells2005 · 11 citations
4Differential expression of IFN-α subtypes in human PBMC: evaluation of novel real-time PCR assays2003 · 57 citations
5Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy2003 · 382 citations